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Introduction
 
Outcomes research, including pharmacoeconomic
and health economic research, is conducted to pro-
vide stakeholders (patients, physicians, institutional
providers, health benefit plan decision-makers, gov-
ernment authorities) with information about the
value of pharmaceuticals, medical devices and medi-
cal procedures. Outcomes research is valuable to a
stakeholder only if the data are relevant for that
stakeholder and the information is received at a
time and in a format that can assist the stakeholder
in a decision about the use of the product or ser-
vice. Outcomes research information is not useful
if it has limited application (e.g., the cost data do
not apply to the stakeholder’s setting) or it is re-
ceived after a decision about the use of the product
or service has been made.
Under our current system of health care deliv-
ery, outcomes research can be especially useful at
the time a new product is introduced; a time when
physicians, providers, patients and payers all have
questions about the clinical and economic impact
of a new treatment on the management of patients
with the target disorder. At the time a new product
is introduced, most of the data about it will have
been gathered under the sponsorship of a corporate
developer (pharmaceutical, biotechnology or medi-
cal device manufacturer). These corporate develop-
ers are regulated by the US Food and Drug Admin-
istration (FDA), and the dissemination of outcomes
research information by these companies must com-
ply with applicable FDA rules. When do those rules
apply and what are the standards for dissemination
of outcomes research information?
 
FDA Regulation of 
Promotional Communications
 
FDA only regulates communications by those who
commercialize drugs, biologicals or medical de-
vices in interstate commerce. FDA does not regu-
late scientific communications among researchers
or practitioners. The two critical factors in analyz-
ing whether FDA jurisdiction applies are: 1) com-
mercialization and 2) interstate commerce. In the-
ory, physicians and institutional providers may be
viewed as commercializing products if they are in
the chain of distribution of a product (e.g., hospi-
tals with their own pharmacies selling to patients).
However, FDA has only very rarely held providers
to the same requirements to which product manu-
facturers are held, for example, where providers
advertise that they provide a particular product. In
today’s global economy, the interstate commerce
requirement is nearly always met.
As well, the FDA does not regulate all com-
munications by product manufacturers. FDA only
regulates promotional communications. Which com-
munications are promotional? Some are clearly pro-
motional, such as product advertisements. Some com-
munications are just as clearly not promotional, such
as a manufacturer responding to an unprompted
telephone call from a physician inquiring about
any available clinical literature on an off-label use
of marketed product. Other communications may
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be less clear whether or not they are promotional.
For example, when a manufacturer sponsors a con-
tinuing education program, is that promotional? It
depends whether the manufacturer has control over
the content of the program. In such a case it is likely
that the program would be considered promotional.
If the manufacturer simply provides funding for a
program but leaves decisions about the content of
the program to an independent continuing education
provider, the program likely would not be consid-
ered promotional.
In general, communications coming from or spon-
sored by a product manufacturer can be separated
into two categories:
• promotional communications intended to ad-
vance the commercial success of a product;
• other nonpromotional communications, which
may include medical communications in response
to physician requests for information, scientific
communications about research at professional
meetings, and communications responding to re-
quirements from governmental agencies.
What is the role of the FDA in regulating promo-
tional communications? The Federal Food, Drug and
Cosmetic Act prohibits the dissemination of promo-
tional materials that are false or misleading (21 USC
§352(a)). If a manufacturer disseminates information
about a product that the FDA considers false or mis-
leading, the product may be considered misbranded,
and the FDA can take action against the product
manufacturer. Penalties can range from requiring the
manufacturer to stop disseminating the false informa-
tion to seizure of the product or criminal penalties.
The historical standard used by the FDA to de-
termine whether information about a product was
false or misleading was the presence of “substantial
evidence” established by “adequate and well-con-
trolled trials.” This generally meant that a manu-
facturer was required to have data from well-con-
trolled trials—usually randomized controlled trials
or RCTs—to support each statement about a prod-
uct used in promotional communications. This is
still the standard applied when assessing the ade-
quacy of substantiation supporting promotional
claims concerning the safety or effectiveness of a
product.
 
FDA Regulation of Outcomes Research 
Communications Under FDAMA Section 114
 
As the importance of pharmacoeconomic and out-
comes research information has increased over the
last 10 years, it has become clear that the standard
of adequate and well-controlled trials does not
work well for many economic analyses. Is resource
utilization information sufficient when collected
from a classic well-controlled RCT? Is there an
adequate and well-controlled method of assigning
costs from a payer database? It is difficult to fit eco-
nomic models to an adequate and well-controlled
trials standard because economic models inherently
require extrapolation from clinical events shown in
well-controlled trials to other endpoints (longer-term
follow up, uncontrolled settings).
To address concerns that FDA regulation was
limiting the development and dissemination of out-
comes research, Congress included a section in the
1997 Food and Drug Administration Moderniza-
tion Act (FDAMA) which set a standard different
from the adequate and well-controlled trials stan-
dard for promotional dissemination of health care
economic information to managed care organization
formulary committees: “competent and reliable sci-
entific evidence” (21 USC §352(a) as amended by
Section 114 of PL 105–115 and commonly referred
to as Section 114).
Although Section 114 did not require the FDA
to promulgate regulations for the new standard to
be effective, many in the outcomes research com-
munity felt it would be helpful for FDA to issue
written guidance explaining the Agency’s under-
standing of the new law. To assist this process, the
Health Outcomes Committee of the Pharmaceutical
Research and Manufacturers Association (PhRMA)
developed a draft guidance, which was submitted to
FDA in June 1998. (http://www.PhRMA.org/issues/
fda/6–22–98.html). In developing the draft guid-
ance, the PhRMA group worked closely with the In-
ternational Society for Pharmacoeconomics and
Outcomes Research (ISPOR) and sought input from
ISPOR, the Society for Medical Decision Making, the
Academy of Managed Care Pharmacy, the American
Pharmaceutical Association, and other relevant
groups.
In their draft guidance, PhRMA discussed the
historical framework behind Section 114 and pro-
posed guidance on the following terms in the new
law:
• health care economic information;
• managed care or other similar organizations;
• formulary committee or other similar entity;
• directly related to an approved indication; and
• competent and reliable scientific evidence.
The PhRMA guidance took a broad, but rea-
sonable, approach to interpretation of Section 114,
consistent with the intent of Congress that Section
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114 would increase the dissemination of outcomes
research information by product manufacturers to
managed care organizations.
The PhRMA Health Outcomes Committee con-
cluded that the Section 114 term 
 
health care eco-
nomic information
 
 should include all forms of eco-
nomic analysis, allowing the guidance to adapt to
the evolving discipline of outcomes research with-
out requiring an update each time a new tweak on
economic analysis methodology is published. Sim-
ilarly, to meet changing arrangements between pro-
viders and payers, PhRMA proposed inclusion of all
forms of managed care and any decision-making
body within those using the categorizations 
 
man-
aged care or other similar organizations
 
 and 
 
for-
mulary committee or other similar entity.
 
 Under
this proposal, a single individual such as a man-
aged care medical director would be encompassed
by the phrase 
 
formulary committee, or other similar
entity
 
 if that individual had the authority to select
products for plan beneficiaries.
One of the more difficult phrases to interpret in
Section 114 is the limitation that promotion must
involve a claim that 
 
directly relates to an indica-
tion approved [by the FDA].
 
 In their draft guid-
ance, PhRMA proposed that extrapolation from
data included on labeling would be appropriate
under the following circumstances:
• from duration of use in labeling to actual dura-
tion of use found in pharmacy utilization data-
bases;
• from dosages included in labeling to actual
dosages found in pharmacy utilization data-
bases; and
• from clinical trial settings to actual practice
settings.
The standard set by Section 114 of 
 
competent
and reliable scientific evidence
 
 is the same stan-
dard used for years by the Federal Trade Commis-
sion (FTC) when assessing the adequacy of sub-
stantiation for manufacturer claims involving over-
the-counter drug products and products affecting
environmental health. That standard requires trans-
parency of methods and conformance with meth-
ods accepted by experts in the field. The PhRMA
proposal recommended that FDA follow long-estab-
lished FTC practice in applying this new standard.
To date the FDA has not released its own guid-
ance, nor has the Agency formally commented on
the PhRMA proposal. The FDA has offered to dis-
cuss individual cases with manufacturers however,
and FDA staff has been open and forthcoming in
many professional meetings with their views and
 
concerns about promotion of outcomes research
information.
It is noteworthy that Section 114 only covers
health economic data. Health-related quality of life
(HRQoL) claims are considered to fall under the es-
tablished 
 
adequate and well-controlled trials
 
 stan-
dard; FDA has been working on a guidance docu-
ment addressing requirements for HRQoL claims,
and publication of a draft document is expected
shortly.
 
ISPOR Section 114 Industry Survey
 
Section 114 has been the law for over two years,
but in the absence of formal guidance from FDA,
many product manufacturers have been hesitant
to develop promotional materials specifically for
review under the Section 114 standard. In addi-
tion, as promotional materials are, by their nature,
proprietary, little information is shared among
companies about their experiences under Section
114. To understand better what manufacturers have
experienced with respect to Section 114, ISPOR
polled industry members in April 2000. The results
were presented at the May 2000 International Meet-
ing and were published recently [1].
Twenty-two individuals from 15 companies re-
sponded to the survey. As would be expected from
ISPOR membership, respondents were from phar-
macoeconomics or outcomes research departments.
Of the 15 companies responding, 8 had submitted
promotional outcomes research materials to FDA
and 5 had received a response. In 3 of the 5 cases
where a response was received, FDA permitted the
sponsor to use the promotional materials; in two
other cases, FDA required major modifications if
the materials were to be considered acceptable for
promotional use. Only one company reported hav-
ing submitted proposed labeling claims covering
health care economic information to FDA; 5 com-
panies reported submitting HRQoL labeling claims
to FDA. Most companies reported having received
unprompted requests for health care economic in-
formation, and nearly all of those companies have
responded through their medical communications
departments.
 
Conclusions
 
Outcomes research information is useful only if it
provides relevant information to stakeholders and
is received in a timely fashion by stakeholders hav-
ing to make decisions about a particular product
or service. Traditional FDA regulation of promo-
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tional communications by product manufacturers
may restrict dissemination of useful outcomes re-
search information. The intent of Section 114 of
FDAMA was to improve the flow of outcomes re-
search information by setting a different standard
for testing the adequacy of health care economic
information—
 
competent and reliable scientific ev-
idence
 
—from the standard used for claims of ef-
fectiveness and safety—
 
substantial evidence from
adequate and well-controlled trials.
 
Although PhRMA has submitted a proposed
guidance to clarify the terms of Section 114, FDA
has not commented formally on the PhRMA sub-
mission, nor yet released its own guidance in this
area. In the absence of formal guidance, few man-
ufacturers are taking full advantage of Section 114.
Nevertheless, there have been a modest number of
submissions made to FDA under Section 114, and
it appears that manufacturers and the FDA have to
some degree begun to approach agreement about
promotional use of outcomes research informa-
tion. Hopefully, the FDA draft guidances on health
care economic information and HRQoL will be re-
leased in the near future for public comment.
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